Details for Patent: 12,440,499

Which drugs does patent 12,440,499 protect, and when does it expire?

Patent 12,440,499 protects WYNZORA and is included in one NDA.

This patent has thirty-three patent family members in twenty-five countries.

Summary for Patent: 12,440,499

Title:	Topical composition
Abstract:	The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,
Inventor(s):	Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
Assignee:	MC2 Therapeutics Ltd
Application Number:	US18/123,828
Patent Claim Types: see list of patent claims	Use; Composition;

Scope and claims analysis for US Patent 12,440,499 covering calcipotriol-betamethasone polyaphron topical compositions (caprylic/capric triglycerides + isopropyl myristate, pH 7.75)

Executive summary

• US12,440,499 claims a specific polyaphron topical dispersion for psoriasis that combines calcipotriol and betamethasone dipropionate in a two-phase polyaphron structure: continuous aqueous phase plus discontinuous oil phase(s) where the discontinuous oil phase contains caprylic capric triglycerides (CCTG) and isopropyl myristate (IPM) at a 4:1 to 8:1 weight ratio (CCTG:IPM) and the overall composition is at pH 7.75 ± 0.5 (and dependent on ±0.25 in claim 2).
• The claim set tightens scope around (i) presence and dosing ranges of actives and antioxidants, (ii) partitioning of actives into the discontinuous oil phase (≥60 wt%), (iii) optional additional non-solvent oil phase architecture, (iv) aqueous-phase alcohol content (≥4 wt% isopropanol), and (v) chemical stability testing windows.
• The independent claim is composition-centric (not a manufacturing method claim), while claim 11 adds a method-of-treatment covering psoriasis using the claimed composition.

---

What is US Patent 12,440,499 and what does it claim at a high level?

Answer (scope): US12,440,499 claims a topical psoriasis composition that is a polyaphron dispersion with:

• Continuous aqueous phase
• At least one discontinuous oil phase that contains CCTG + IPM in 4:1 to 8:1 weight ratio
• Actives: calcipotriol and betamethasone dipropionate
• Excipients/actives add-ons: alpha-tocopherol and butylated hydroxyanisole (BHA)
• Target pH 7.75 ± 0.5 (or narrower ±0.25 in dependent claim 2)

Why the polyaphron architecture matters for claim scope

Polyaphron dispersions are distinguished by the presence of discontinuous oil “pockets” within a continuous phase, stabilized by surfactant/cosurfactant systems and yielding enhanced partitioning of lipophilic ingredients into oil domains. The claims are written to force:

• A specific dispersion type (polyaphron)
• Specific phase composition (CCTG + IPM as the discontinuous oil phase components)
• Specific pH of the final formulation
• Specific localization/partitioning of at least 60 wt% of each additive/active into discontinuous oil phase(s) (claim 4 and claim 6, where applicable)

Independent claim 1: full element-by-element breakdown

Claim 1 requires all of the following:

1. A composition for topical application.
2. Composition is a polyaphron dispersion with:
   • Continuous aqueous phase
   • At least one discontinuous oil phase
3. The polyaphron dispersion contains:
   • calcipotriol
   • betamethasone dipropionate
   • alpha-tocopherol
   • BHA
4. The at least one discontinuous oil phase comprises:
   • caprylic capric triglycerides
   • isopropyl myristate
5. CCTG:IPM weight ratio = 4:1 to 8:1
6. pH = 7.75 ± 0.5

Practical implication: An accused formulation that misses any single required element (wrong dispersion type, wrong oil components, wrong ratio window, wrong pH band, or missing an antioxidant/active) can be outside claim 1.

---

What dependent claim limitations narrow US12,440,499 coverage beyond the independent claim?

Answer (claim narrowing): Dependent claims add constraints on pH precision, active/excipient amounts, partitioning location, optional additional oil phase, aqueous-phase isopropanol level, and chemical stability under defined storage conditions.

Claim 2: tighter pH band

• pH of the composition is 7.75 ± 0.25.

Scope effect: If a competitor targets pH 7.75 but drifts toward the outer part of ±0.5 (for example 7.26 or 8.24), it could avoid claim 2 while still falling within claim 1.

Claim 3: quantitative range for key components

Claim 3 requires the composition to include, by weight:

• calcipotriol: 0.001 to 0.01 wt%
• betamethasone dipropionate: 0.02 to 0.1 wt%
• alpha-tocopherol: 0.001 to 0.005 wt%
• BHA: 0.05 to 0.5 wt%

Scope effect: This is a multi-parameter “window” claim. A generic or reformulated product outside any range avoids claim 3 while potentially still implicating claim 1 (if claim 1 does not itself specify quantitative ranges).

Claim 4: partitioning into discontinuous oil phase (≥60 wt%)

Claim 4 covers:

• polyaphron having at least one discontinuous oil phase, and
• for each component listed, at least 60 wt% is in the discontinuous oil phase:
  • calcipotriol
  • betamethasone dipropionate
  • alpha-tocopherol
  • BHA

Scope effect: This is a structural-quantitative functional distribution requirement. It can be a strong barrier because many formulations may “contain” components but do not ensure ≥60 wt% of each component resides in the discontinuous oil phase (depending on solvent partitioning, micelle formation, or surfactant level).

Claim 5: optional extra discontinuous phase (non-solvent oil)

• Polyaphron may further comprise a discontinuous phase with a non-solvent oil.

Scope effect: This is not a restriction but a structural allowance. It supports broader protection for variants with additional discontinuous oil phase(s).

Claim 6: phase allocation across multiple discontinuous phases

Claim 6 introduces specificity when there are multiple discontinuous phases:

• discontinuous oil phase comprises:
  • first discontinuous phase
  • second discontinuous phase
  • optional third discontinuous phase comprising mineral oil
• Partition requirements:
  • ≥60 wt% of calcipotriol in the first discontinuous phase
  • ≥60 wt% of betamethasone dipropionate in the second discontinuous phase
  • ≥60 wt% of alpha-tocopherol and BHA in the first phase, or in the first and second phases collectively

Scope effect: This forces a specific “division of labor” for actives across phases. A competitor may still land in claim 1 but could avoid claim 6 if distribution differs.

Claim 7: aqueous phase isopropanol content

• continuous aqueous phase comprises at least 4 wt% isopropanol by weight of the composition.

Scope effect: This limits formulations that substitute another co-solvent or use lower isopropanol levels.

Claim 8: chemical stability windows

Claim 8 requires one or both stability metrics:

• chemically stable for ≥6 months at 25° C ±2° C, 60% RH ±5%
• chemically stable for ≥12 months at 5° C ±3° C, 60% RH ±5%

Scope effect: These are performance/storage claims. A competitor’s stability profile could matter in infringement analysis and in litigation through testing and stability reports.

---

How does claim 9 and claims 10-11 expand or repeat the scope?

Claim 9: parallel independent composition claim without antioxidants in the base wording

Claim 9 repeats core architecture:

• polyaphron dispersion with continuous aqueous and discontinuous oil phase(s)
• discontinuous oil phase comprises CCTG + IPM
• CCTG:IPM = 4:1 to 8:1
• contains calcipotriol and betamethasone dipropionate
• no explicit recitation of alpha-tocopherol and BHA in the independent text of claim 9

Claim 10: adds alpha-tocopherol

• claim 10 depends from claim 9 and adds alpha-tocopherol.

Scope effect: The claim set gives layered protection:

• If a formulation omits BHA, it might avoid claim 1 but could still fall within claim 9 (depending on whether BHA is present/required elsewhere).
• If a formulation omits alpha-tocopherol, it might avoid claim 10 but still could be within claim 9.

Claim 11: method-of-treating psoriasis

• administering an effective amount of the composition of claim 1 to a human or animal subject for psoriasis.

Scope effect: Method claims are typically pursued in parallel with composition claims. For enforcement, it links infringement to use of the claimed formulation in psoriasis treatment.

---

What is the patent landscape around calcipotriol + betamethasone topical psoriasis products in polyaphron systems?

Answer (landscape framing): Based on the claim structure, the competitive threat model is not “any generic of calcipotriol/betamethasone,” but topical delivery systems that preserve:

• the polyaphron dispersion class
• the CCTG + IPM discontinuous oil phase
• ratio and pH constraints
• the partitioning of actives and antioxidants into the discontinuous oil phase(s)

Likely high-risk design-around targets (what not to miss)

• Wrong discontinuous oil system: If a competitor replaces IPM with another ester or changes triglycerides away from CCTG, it likely exits claim 1/9’s required oil system.
• Wrong ratio window: If CCTG:IPM is outside 4:1 to 8:1, it exits claim 1 and claim 9.
• Wrong pH: pH outside 7.75 ± 0.5 avoids claim 1; outside 7.75 ± 0.25 avoids claim 2.
• Missing antioxidants: If BHA or alpha-tocopherol is absent, claim 1 may be avoided (depending on how claim 9 is asserted).
• Distribution failures: If actives and antioxidants are not present ≥60 wt% in discontinuous oil phase(s), then claim 4 and claim 6 may be avoided even if the formulation is otherwise structurally similar.

Likely low-risk areas for competitors (design direction)

• Use a non-polyaphron topical emulsion or gel system with different microstructure, even if containing the same actives, because the claim specifically limits to polyaphron dispersions.
• Switch the discontinuous phase oils to different oils or vary the ratio outside the claimed range.
• Use a different pH target for stability and tolerability.

---

What are the key claim-interpretation and proof points for infringement or invalidity?

Answer (litigation levers): The claim’s enforceability turns on (i) whether a product is truly a polyaphron dispersion, (ii) whether phase composition and ratios match, and (iii) whether distribution (≥60 wt%) and pH/stability meet the testable limitations.

1) “Polyaphron dispersion” classification

• Litigation will likely require expert characterization and test methodology showing the product’s internal phase structure is within the polyaphron definition used in the patent.

2) CCTG and IPM and the 4:1 to 8:1 weight ratio

• Proof depends on accurate formulation disclosure or forensic formulation analysis (if not controlled by discovery).
• The ratio is limited as a range, so product variances must be measured.

3) pH of 7.75 ± 0.5 (and narrower ±0.25)

• pH can shift with temperature, time after mixing, and storage. Claim 1 and claim 2 require the composition pH to fall within narrow tolerance.

4) Partitioning: ≥60 wt% of actives/additives into discontinuous oil phase

• This is a quantitative functional requirement.
• Expect disputes around:
  • extraction method to separate phases
  • whether surfactants or emulsifiers are accounted for as part of continuous vs discontinuous phase
  • stability-related migration that changes distribution over time

5) Chemical stability metrics

• Claim 8 depends on meeting defined stability time-and-temperature-and-humidity thresholds.
• If a competitor’s product degrades faster under the same conditions, claim 8 may be avoidable even if composition and structure are otherwise similar.

---

How strong is US12,440,499 as a barrier to generic entry or reformulation?

Answer (strength): Strength is highest against products that replicate:

• the specific polyaphron class
• the CCTG/IPM discontinuous oil phase with 4:1 to 8:1 ratio
• and meet pH and partitioning limits

Why this is a higher bar than “active ingredient sameness”

• Many competing products can match calcipotriol and betamethasone dosage but use different solvents, emulsifier systems, and microstructures.
• This claim set targets microstructure + phase composition + pH + quantitative partitioning.

What a likely generic or biosimilar-style challenge would look like (conceptually)

• For infringement disputes, challengers would likely argue:
  • non-polyaphron microstructure
  • ratio outside the window
  • pH outside tolerance
  • distribution not ≥60 wt% in discontinuous oil phase
• For validity disputes, challenges would likely focus on prior art that discloses polyaphron topical systems with similar oils and pH and actives, but the exact matching of ratio and partitioning could raise the bar for invalidity.

---

Can a competitor avoid infringement while using the same actives (design-around map)?

Answer: Yes, based on the claim’s “hard stops.” Below is a non-exhaustive design-around map tied to each limiting element.

Element-by-element design-around triggers

• Remove BHA: may avoid claim 1 but not claim 9 (unless claim 9 is asserted with additional dependencies).
• Change CCTG/IPM ratio:
  • to <4:1 or >8:1 to exit claim 1 and claim 9
• Change pH:
  • outside 7.25 to 8.25 avoids claim 1
  • outside 7.5 to 8.0 avoids claim 2
• Avoid polyaphron:
  • use a different dispersion system (emulsion, ointment, gel) even with same oils and actives
• Fail ≥60 wt% partitioning:
  • distribute actives differently between phases, or reduce the fraction residing in discontinuous oil
• Drop isopropanol below 4 wt%:
  • avoids claim 7
• Fail stability window:
  • degrade under specified storage conditions to avoid claim 8

---

What is the commercial and regulatory exposure implied by the claim set?

Answer: The regulatory exposure is tied to the marketed topical product that uses calcipotriol and betamethasone. The patent’s risk profile is highest for:

• branded reformulations using a polyaphron system with CCTG/IPM oils
• ANDA-style “same-actives/same-strength” approaches that also replicate the claimed delivery system
• any distributor or contract manufacturer whose process yields the claimed phase structure and pH

Method-of-use linkage

Claim 11 ties infringement to use in psoriasis treatment with the claimed composition. Even if a product is sold generally for dermatology, enforcement can focus on labeled or promotional psoriasis use if the product is within claim 1’s composition scope.

---

Key Takeaways

• US12,440,499 is a phase- and microstructure-specific topical psoriasis patent built on a polyaphron dispersion containing calcipotriol + betamethasone dipropionate with CCTG + IPM discontinuous oil phase at 4:1 to 8:1 and pH 7.75 ± 0.5.
• The strongest claim “hard stops” are: polyaphron classification, CCTG/IPM composition and ratio, pH, and ≥60 wt% partitioning into discontinuous oil phase.
• Dependent claims further narrow scope through precise pH, component weight ranges, multi-phase allocation, ≥4 wt% isopropanol, and defined chemical stability windows.
• Claim 11 adds enforcement leverage by covering psoriasis treatment using the composition of claim 1.

---

FAQs

1. What formulation changes most reliably avoid infringement of US12,440,499? Changing the discontinuous oil system away from CCTG + IPM, moving CCTG:IPM outside 4:1 to 8:1, or targeting pH outside 7.75 ± 0.5.
2. If a product matches actives and dosage but is not a polyaphron dispersion, can it still infringe? It would likely miss the “polyaphron dispersion” limitation that is required for claims 1 and 9.
3. How do the ≥60 wt% partitioning requirements affect design-around strategies? A formulation can be compositionally similar yet avoid claims 4 and 6 if actives/antioxidants do not reside at ≥60 wt% in the discontinuous oil phase under the claim’s measurement logic.
4. Does omitting alpha-tocopherol or BHA eliminate risk entirely? Not necessarily. Omitting BHA may avoid claim 1 but could still leave risk under claim 9 (and alpha-tocopherol dependency in claim 10 depends on which claims are asserted).
5. What role do stability tests play in infringement for this patent? Claim 8 can be asserted only if the product meets the defined time-temperature-RH stability thresholds; testing and stability reports become central in disputes around that dependent claim.

---

References

No sources were cited because no bibliographic details (publication number, assignee, filing dates, cited prior art, prosecution history, or Orange Book/FDA product linkage) were provided in the prompt.

Drugs Protected by US Patent 12,440,499

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422-001	Jul 20, 2020		RX	Yes	Yes	12,440,499		Y			TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

International Family Members for US Patent 12,440,499

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019239544
Brazil	112020019075
Canada	3093999
China	111867563
China	113499343
Cyprus	1124719
Denmark	3768241